Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 14INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 3Part 1:r/r B-cell Malignancies 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Hematologic Neoplasms 1

Interventions

Rituximab 23Lenalidomide 11Cyclophosphamide 10zanubrutinib 9Bendamustine Hydrochloride 8venetoclax 6ibrutinib 6fludarabine 6parsaclisib 5idelalisib 5ublituximab 4obinutuzumab 4aflibercept 4Prednisone 4pirtobrutinib 3Vincristine 3ME-401 3Doxorubicin 3umbralisib 2tazemetostat 2marizomib 2epratuzumab 2Radioimmunodetection 2voruciclib 1veltuzumab 1varlilumab 1tislelizumab 1tetulomab tetraxetan lu-177 1tafasitamab 1repaglinide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, B-Cell, Marginal Zone × orelabrutinib × Clear all
NCT06082102 2025-09-15

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Beijing InnoCare Pharma Tech Co., Ltd.

Phase 3 Recruiting
324 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡